Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GlucoTrack ( (GCTK) ) has provided an announcement.
On January 29, 2026, Glucotrack, Inc. announced that the U.S. Patent and Trademark Office had issued three patents in late 2025 covering key technologies underpinning its fully implantable continuous blood glucose monitoring platform, including proprietary sensor chemistry, intravascular lead design, and low-power electronics, which together aim to bridge the gap between short-lived subcutaneous sensors and larger pacemaker-class devices. The new patents bolster Glucotrack’s intellectual property protection and competitive position as it advances its multi-year CBGM system—designed to directly measure glucose from blood for up to three years of continuous, lag-free monitoring without a wearable component—through further clinical testing and toward eventual commercialization, reinforcing its strategic push to offer a more convenient, less burdensome diabetes management solution.
The most recent analyst rating on (GCTK) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on GlucoTrack stock, see the GCTK Stock Forecast page.
Spark’s Take on GCTK Stock
According to Spark, TipRanks’ AI Analyst, GCTK is a Neutral.
The score is held down primarily by extremely weak financial performance (minimal revenue, widening losses, heavy cash burn, and negative equity) and bearish technicals (below key moving averages with negative MACD). Valuation offers limited support due to ongoing losses and no dividend, while recent financing provides some near-term capital relief but does not offset the underlying fundamentals.
To see Spark’s full report on GCTK stock, click here.
More about GlucoTrack
Glucotrack, Inc. (Nasdaq: GCTK) is a medical device company focused on designing, developing, and commercializing novel technologies for people with diabetes, currently centered on a long-term, fully implantable continuous blood glucose monitoring (CBGM) system that offers up to three years of sensor longevity, no on-body wearable component, and minimal calibration, and is presently classified as an investigational device under U.S. law.
Average Trading Volume: 84,237
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.11M
See more insights into GCTK stock on TipRanks’ Stock Analysis page.